Inclusion Criteria:  Subject's signed Informed Consent Form; Male or female ≥ 40 years of age; Current smokers or ex-smokers of at least 10 pack-years, Established diagnosis of COPD Post-BD Forced Expiratory Volume in one second/Forced Vital Capacity (FEV1/FVC) < 0.7 and FEV1 ≤ 60% of predicted at V1 On a stable dose any non-extra fine ICS/LABA DPI twice daily regimen for at least 8 weeks before screening; Presence of lung hyperinflation Symptomatic subjects with COPD assessment test (CAT) score ≥ 10; Documented history of ≥ 1 moderate or severe COPD exacerbation in the previous 12 months  Exclusion Criteria:  Pregnant or lactating woman; Exacerbations defined as a sustained and acute deterioration of subject's symptoms and signs 30 days before screening; A current asthma diagnosis; Respiratory disorders other than COPD: Cardiovascular diseases; Evidence or history of other concurrent disease such as but not limited to hyperthyroidism, diabetes mellitus or other endocrine disease; Medical history or current diagnosis of narrow-angle glaucoma; History of lung transplant or lung reduction surgery; ECG criteria: any clinically significant abnormal 12-lead ECG that in the investigator's opinion would affect efficacy or safety evaluation or place the subjects at risk; Laboratory abnormalities; Alcohol/drug abuse; Contra-indications to Investigational medical products (IMPs), based on investigator judgement; Documented Covid-19 diagnosis or its complications which have not resolved within 14 days prior to screening;  15. Positive molecular Covid-19 test within the last 72 hours before the remaining of screening activities.